Low serum magnesium concentrations predict cardiovascular and all-cause mortality

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 280-284

  Reffelmann, Thorsten ^a   Ittermann, Till ^a,b   Dörr, Marcus ^a   Völzke, Henry ^b   Reinthaler, Markus ^a   Petersmann, Astrid ^a   Felix, Stephan B ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Cardiovascular; Epidemiology; Hypertension; Left ventricular mass; Magnesium; Mortality

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOMAGNESEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; GERMANY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MAGNESIUM; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 80054998703     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.05.038     Document Type: Article

References (27)

1. Reffelmann T., Dörr M., Ittermann T., et al. Low serum magnesium concentrations predict increase in left ventricular mass over five years independently of common cardiovascular risk factors. Atherosclerosis 2010, 213:563-569.
2. Kannel W.B., Cobb J. Left ventricular hypertrophy and mortality: results from the Framingham Study. Cardiology 1992, 81:291-298.
3. Devereux R.B., Wachtell K., Gerdts E., et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004, 292:2350-2356.
4. de Simone G., Gottdiener J.S., Chinali M., Maurer M.S. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J 2008, 29:741-747.
5. Verdecchia P., Angeli F., Borgioni C., et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003, 16:895-899.
6. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 323:1706-1707.
7. Dawson E.B., Frey M.J., Moore T.D., McGanity W.J. Relationship of metal metabolism to vascular mortality rates in Texas. Am J Clin Nutr 1978, 31:1188-1197.
8. Yang C.Y., Chiu H.F., Chiu J.F., Wang T.N., Cheng M.F. Magnesium and calcium in drinking water and cerebrovascular mortality in Taiwan. Magnes Res 1997, 10:51-57.
9. Khan A.M., Sullivan L., McCabe E., et al. Lack of association between serum magnesium and the risks of hypertension and cardiovascular disease. Am Heart J 2010, 160:715-720.
10. Sontia B., Touyz R.M. Magnesium transport in hypertension. Pathophysiology 2007, 14:205-211.
11. Sapna S., Ranjith S.K., Shivakumar K. Cardiac fibrogenesis in magnesium deficiency: a role for circulating angiotensin II and aldosterone. Am J Physiol Heart Circ Physiol 2006, 291:H436-H440.
12. Barbagallo M., Dominguez L.J. Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. Arch Biochem Biophys 2007, 458:40-47.
13. Völzke H., Alte D., Schmidt C.O., et al. Cohort Profile: The study of Health in Pomerania. Int J Epidemiol 2011, 40:294-307.
14. Gitleman H.J., Hurt C., Lutwak L. An automated spectrophotometric method for magnesium analysis. Anal Biochem 1966, 14:106.
15. Pesce A.J., Kaplan L.A. Methods in clinical chemistry 1987, C.V. Mosby Company, St. Louis, MO, p. 1041.
16. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
17. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006, 7:79-108.
18. Yamori Y., Taguchi T., Mori H., Mori M. Low cardiovascular risks in the middle aged males and females excreting greater 24-hour urinary taurine and magnesium in 41 WHO-CARDIAC study populations in the world. J Biochem Sci 2010, 17(Suppl. 1):S21.
19. Joffres M.R., Reed D.M., Yano K. Relationship of magnesium intake and other dietary factors to blood pressure. The Honolulu Heart Study. Am J Clin Nutr 1987, 45:469-475.
20. Staessen J., Bulpitt C., Fagard R., et al. Four urinary cations and blood pressure. A population study in two Belgian towns. Am J Epidemiol 1983, 117:676-687.
21. Kesteloot H., Huang D.X., Li Y.L., Geboers J., Joossens J.V. The relationship between cations and blood pressure in People's Republic of China. Hypertension 1987, 9:654-659.
22. Jee S.H., Miller E.R., Guallar E., et al. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens 2002, 15:691-696.
23. Kao W.H., Folsom A.R., Nieto F.J., et al. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med 1999, 159:2151-2159.
24. Adamopoulos C., Pitt B., Sui X., et al. Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. Int J Cardiol 2009, 136:270-277.
25. Woods K.L., Fletcher S., Roffe C., Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992, 339:1553-1558.
26. ISIS-1: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995, 345:669-685. ISIS-4 Collaborative Group.
27. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002, 360:1189-1196. The Magnesium in Coronaries Trial Investigators.